This suggests that targeting mitochondrial Akt is a potential therapeutic approach to improve cardiac insulin-stimulated glucose oxidation in the setting of heart failure, obesity and diabetes, situations where the heart is insulin resistant. Here, AKT1 is linked to heart failure.